Publications by authors named "Caroline Regny"
Background: Autoimmune conditions in B-cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved for B-cell indolent lymphoma treatment.
View Article and Find Full Text PDFAngioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy. Lenalidomide, which has been safely combined with CHOP to treat B-cell lymphoma, has shown efficacy as a single agent in AITL treatment. We performed a multicentric phase 2 trial combining 25 mg lenalidomide daily for 14 days per cycle with 8 cycles of CHOP21 in previously untreated AITL patients aged 60 to 80 years.
View Article and Find Full Text PDFComposite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases.
Br J Haematol
April 2020
Article Synopsis
- Composite and sequential lymphomas involving classical Hodgkin lymphoma (CHL) and primary mediastinal B-cell lymphoma (PMBCL) are rare and not well-studied, with this analysis focusing on 25 cases (10 composite and 15 sequential).
- The research found that 70% of composite lymphomas were advanced at diagnosis, and sequential lymphomas were categorized based on the timing of the second diagnosis—early (within a year) or late (after a long remission).
- The study highlighted that while early sequential lymphomas had poor outcomes (average survival less than a year), late cases responded well to treatment, underscoring the need for more research into the biology of these complex lymphomas.
Introduction: Long-term efficacy of anti-PD1 therapy and the need for a consolidation with allogenic haematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL).
Methods: We retrospectively analysed 78 patients with R/R HL treated with nivolumab in the French Early Access Program and compared their outcomes according to subsequent allo-HSCT.
Results: After a median follow-up of 34.
The question of the best donor type between haploidentical (HAPLO) and matched-related donors (MRD) for patients with advanced HL receiving an allogeneic hematopoietic cell transplantation (allo-HCT) is still debated. Given the lack of data comparing these two types of donor in the setting of non-myeloablative (NMA) or reduced-intensity (RIC) allo-HCT, we performed a multicentre retrospective study using graft-vs.-host disease-free relapse-free survival (GRFS) as our primary endpoint.
View Article and Find Full Text PDFArticle Synopsis
- * Most patients (91%) exhibit extranodal involvement, often affecting the central nervous system, skin, or testicles, and the majority of cases analyzed showed a non-germinal center B-cell phenotype.
- * First-line treatment typically involves an R-CHOP regimen, achieving a 61% response rate, but the overall survival after transformation is only 16 months, with worse outcomes linked to delayed transformation and elevated LDH levels.
Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.
Haematologica
February 2015
Article Synopsis
- * A multicenter phase II trial examined a regimen using fludarabine, intravenous busulfan, and rabbit antithymocyte globulins in patients over 55 years, finding low rates of serious graft-versus-host disease and non-relapse mortality.
- * Results indicated that over 75% of patients maintained their quality of life, with good survival rates and high rates of being progression-free at the one-year mark.
The impact of consolidation on response rates and PFS has recently been demonstrated after induction and autotransplantation upfront in Multiple Myeloma (MM). We further showed that patients in ≥VGPR following the intensification procedure benefited most from consolidation. Question remains as to the benefit of consolidation for patients in PR at completion of induction - feature of partial resistance to the induction regimen.
View Article and Find Full Text PDF